Adicet Bio (Nasdaq:ACET) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ACET Stoklara Genel Bakış

Klinik aşamada bir biyoteknoloji şirketi olan Adicet Bio, Inc. otoimmün hastalıklar ve kanser için allojenik gama delta T hücre tedavileri keşfetmekte ve geliştirmektedir.

Şirket hakkında

ACET temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 93.3% daha düşük bir oranda işlem görüyor

Gelirin yılda 73.79% oranında artması öngörülüyor

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $0 )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Adicet Bio, Inc. Rakipler

Anixa Biosciences

NasdaqCM:ANIX

US$100.7m

MediciNova

NasdaqGM:MNOV

US$97.6m

Adverum Biotechnologies

NasdaqCM:ADVM

US$154.8m

Shattuck Labs

NasdaqGS:STTK

US$53.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Adicet Bio
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.43
52 Haftanın En Yüksek Seviyesi	US$3.77
52 Haftanın En Düşük Seviyesi	US$1.05
Beta	1.68
11 Aylık Değişim	-3.38%
3 Aylık Değişim	12.60%
1 Yıllık Değişim	0%
33 Yıllık Değişim	-80.62%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-90.71%

Son Haberler & Güncellemeler

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Jul 12

Recent updates

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Jul 12

Adicet Bio: Microcap With A High Risk To Reward Ratio

May 23

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 01

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Dec 20

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Oct 17

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Oct 04

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Aug 16

Adicet Bio: A First Take

Jul 22

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Jul 07

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

May 15

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Mar 18

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Feb 09

Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management

Dec 28

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Dec 16

Hissedar Getirileri

	ACET	US Biotechs	US Pazar
7D	0.7%	-1.1%	0.6%
1Y	0%	17.1%	30.3%

Getiri vs. Endüstri: ACET geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: ACET geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ACET's price volatile compared to industry and market?
ACET volatility
ACET Average Weekly Movement	8.9%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: ACET son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ACET 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	143	Chen Schor	www.adicetbio.com

Klinik aşamada bir biyoteknoloji şirketi olan Adicet Bio, Inc. otoimmün hastalıklar ve kanser için allojenik gama delta T hücre tedavileri keşfetmekte ve geliştirmektedir. Şirket, hastalarda kalıcı aktiviteyi kolaylaştırmak için kimerik antijen reseptörleri (CAR'lar) ile tasarlanmış gama delta T hücreleri sunmaktadır. Şirketin öncü ürün adayı, otoimmün hastalıkların ve nükseden veya refrakter agresif B hücreli non-Hodgkin lenfomanın tedavisi için Faz I klinik çalışmasında olan CD20'yi hedefleyen bir CAR ifade eden allojenik bir gama delta T hücre tedavisi olan ADI-001'dir.

Adicet Bio, Inc. Temel Bilgiler Özeti

Adicet Bio'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ACET temel i̇stati̇sti̇kler
Piyasa değeri	US$116.19m
Kazançlar(TTM)	-US$137.29m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.9x

F/K Oranı

ACET aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ACET gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$137.29m
Kazançlar	-US$137.29m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.67
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

ACET uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ACET Stoklara Genel Bakış

Ödüller

Risk Analizi

Adicet Bio, Inc. Rakipler

NasdaqCM:ANIX

US$100.7m

NasdaqGM:MNOV

US$97.6m

NasdaqCM:ADVM

US$154.8m

NasdaqGS:STTK

US$53.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Recent updates

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio: Microcap With A High Risk To Reward Ratio

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Price target decreased by 18% to US$12.80

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Price target decreased by 15% to US$18.29

New minor risk - Market cap size

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Price target decreased by 14% to US$23.29

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Price target decreased by 7.8% to US$25.44

Consensus EPS estimates upgraded to US$2.42 loss

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 180%, EPS downgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Chief Technology Officer notifies of intention to sell stock

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Consensus forecasts updated

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

CEO, President & Director notifies of intention to sell stock

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Now 23% undervalued after recent price drop

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Consensus forecasts updated

Consensus revenue estimates fall by 34%

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Adicet Bio: A First Take

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

Consensus revenue estimates increase by 42%

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting